The 2025-2030 World Outlook for Biologics

The 2025-2030 World Outlook for Biologics

This study covers the world outlook for biologics across more than 190 countries. For each year reported, estimates are given for the latent demand, or potential industry earnings (P.I.E.), for the country in question (in millions of U.S. dollars), the percent share the country is of the region, and of the globe. These comparative benchmarks allow the reader to quickly gauge a country vis-à-vis others. Using econometric models which project fundamental economic dynamics within each country and across countries, latent demand estimates are created. This report does not discuss the specific players in the market serving the latent demand, nor specific details at the product level. The study also does not consider short-term cyclicalities that might affect realized sales. The study, therefore, is strategic in nature, taking an aggregate and long-run view, irrespective of the players or products involved.

In this report we define the sales of biologics as including all commonly understood products falling within this broad category, irrespective of product packaging, formulation, size, or form. Companies participating in this industry include 3SBio, AbbVie, Ablynx, ACCELERON PHARMA, Accord Healthcare, Aché, Actavis, Adaptive Biotechnologies Corporation, Advanced BioHealing, Advantagene, Advaxis, Afferent Pharmaceuticals, Alder Biopharmaceuticals, Alector, Allergan, Alteogen, AMEGA Biotech, Amgen, AM‐Pharma, Anacor Pharmaceuticals, AnGes, Anthera Pharmaceuticals, Apceth, Apeiron Biologics, Apotex, argenx, ARMO Biosciences, Inc., Aryogen, Aspen Global, Inc., Astellas Pharma, AstraZeneca, AurKa Pharma, Inc., Aventis, Avita Medical, Bamboo Therapeutics, Inc., Banner Alzheimer's Institute, Basilea Pharmaceutica, Baxalta, Bayer, Beijing Four Rings, Benda Pharmaceuticals, Bharat Biotech, BIOCAD, BioCardia, Biocon, Biodel, Biogen, Bionovis, Biopartners, Biopharma, Biosidus, Biotest, Bioton, BioXpress Therapeutics, Boehringer Ingelheim, BrainStorm Cell Therapeutics, Bristol-Myers Squibb, Cambridge Antibody Technology, cCAM Biotherapeutics, CCL Pharmaceuticals, Celgene Corporation, Celltrion, CEL-SCI, Centocor Ortho Biotech, Children’s Oncology Group, CHMP, Chugai, Cinnagen, ClinImmune Labs, CSL Behring, CT Arzneimittel, CureVac, Cystic Fibrosis Foundation Therapeutics, Inc., CytomX Therapeutics, Daiichi Sankyo Company, Dako, Dendreon, Dezima Pharma B.V., DNAtrix, Dong-A Pharmaceutical, Dr. Reddy's Laboratories, Dynavax Technologies, Eisai Company, Eli Lilly and Company, Emcure Pharmaceuticals, EMS, Epirus, Europharm, Evotec, F. Hoffmann-La Roche, FDA, FibroGen, FierceBiotech, Finox Biotech, Flatiron Health, FOUNDATION Medicine, Fuji Pharma, Galencia, Gan & Lee, GE Healthcare, Gennova, GenSci, Genzyme, Gilead Sciences, GlaxoSmithKline (GSK), Hangzhou Jiuyuan Gene Engineering Company, Hanwha Chemical, Harpoon Therapeutics, Harrisvaccines, Inc., Heptares Therapeutics, Hexal, Hindustan Antibiotic, Histogenics, Hospira, Human Genome Sciences, Hypermarcas, IBM Watson Health, ICU Medical, Ignyta, Immatics Biotechnologies, Immune Design, Immunocore, Ltd., Incyte, Innovare R&D, Insmed, Intas Pharmaceuticals, IOmet Pharma, Ipsen, Isis Pharmaceuticals, Janssen, JingYuan Bio, Johnson & Johnson, Kite Pharma, Kyowa Hakko Kirin, Laboratorios Delta, LG Life Sciences, LifeSouth Community Blood Centers, Lonza Group, Luye Pharma Group, M2Gen, MacroGenics, Massachusetts General Hospital, Medice, MedImmune, Medipost, Medivation, Medtronic, PLC, Merck & Company, Merz Pharma, Mirati Therapeutics, Mitsubishi Tanabe, Mochida Pharmaceutical, Moderna Therapeutics, Mylan, Nanostring Technologies, Ngm Biopharmaceuticals, Nippion Kayaku, Northwestern University, Novartis, Novo Nordisk, NuVasive, Oanda, Organogenes, OrLife Bio, Orthofix, Orygen, Peregrine Pharmaceuticals, Pfizer, Pharmacyclics, Pharmicell, Pharmstandard, Plexxikon, Porbiomed, Portola Pharmaceuticals, Precision Biologics, Premier, Principia, Probiomed, Protein Sciences, Proteon Therapeutics, Qilu Pharmaceutical, Ranbaxy, Ratiopharm, Redvax GmbH, Regeneron Pharmaceuticals, Regenerys, Reliance Life Sciences, Rentschler Biotechnologie., Rigontec, Roche, Samsung Bioepis, Sandoz, Sangamo Therapeutics, Sanofi, Schering-Plough, SciGen, Shandong Kexing Pharma, Shanghai CP Guojian Pharmaceutical, Shantha Biotechnics, Shenzhen SiBiono GeneTech, Shire, Sicor Biotech, Sigilon Therapeutics, Simcere Pharmaceutical Group, Smith and Nephew, Spark Therapeutics, STADA, Stemcentrx, Stragen Pharma, Stratatech, Swiss Re, Takeda Pharmaceutical Company, Tesaro, TetraLogic Pharmaceuticals, Teva, Tianjin Hualida Biotechnology, TiGenix, Tonghua Dongbao, Trophos, Turnstone Biologics, UCB, União Química, UniQure, Valeant Pharmaceuticals, Vertex Pharmaceuticals, Viralytics, Vital Therapies, Voyager Therapeutics, Wockhardt, Wyeth-Ayerst Laboratories, Xencor, Xiamen Amoytop Biotech, XO1, Ltd., Zenotech, ZS Pharma, Zuventus, and Zydus Biovation. In addition to the sources indicated, additional information available to the public via news and/or press releases published by players in the industry was considered in defining and calibrating this category. All figures are in a common currency (U.S. dollars, millions) and are not adjusted for inflation (i.e., they are current values). Exchange rates used to convert to U.S. dollars are averages for the year in question. Future exchange rates are assumed to be constant in the future at the current level (the average of the year of this publication's release in 2024).